Cargando…

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study

Background: Pathologic changes in cortical gray matter (GM) and leptomeninges contribute to disability worsening in patients with multiple sclerosis (MS), but there is little evidence whether disease-modifying treatments can slow down cortical pathology in MS. Objectives: To investigate the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zivadinov, Robert, Bergsland, Niels, Carl, Ellen, Ramasamy, Deepa P., Hagemeier, Jesper, Dwyer, Michael G., Lizarraga, Alexis A., Kolb, Channa, Hojnacki, David, Weinstock-Guttman, Bianca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463015/ https://www.ncbi.nlm.nih.gov/pubmed/30870983 http://dx.doi.org/10.3390/jcm8030344

Ejemplares similares

Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes
por: Jakimovski, Dejan, et al.
Publicado: (2021)

Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS
por: Zivadinov, Robert, et al.
Publicado: (2020)

Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI
por: Schweser, Ferdinand, et al.
Publicado: (2020)

Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS
por: Zivadinov, Robert, et al.
Publicado: (2016)

Increased contrast enhancing lesion activity in relapsing–remitting multiple sclerosis migraine patients()
por: Graziano, Elliot, et al.
Publicado: (2015)

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals
por: Hagemeier, Jesper, et al.
Publicado: (2017)

Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients
por: Jakimovski, Dejan, et al.
Publicado: (2020)

No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years
por: Gandhi, Sirin, et al.
Publicado: (2019)

Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Effect of Treatment with Interferon Beta-1a on Changes in Voxel-Wise Magnetization Transfer Ratio in Normal Appearing Brain Tissue and Lesions of Patients with Relapsing–Remitting Multiple Sclerosis: A 24-Week, Controlled Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2014)

Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2020)

Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study
por: Zivadinov, Robert, et al.
Publicado: (2012)

Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain
por: Hagemeier, Jesper, et al.
Publicado: (2017)

Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
por: Tao, Yazhong, et al.
Publicado: (2015)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015)

Quantifying disease pathology and predicting disease progression in multiple sclerosis with only clinical routine T2-FLAIR MRI
por: Fuchs, Tom A., et al.
Publicado: (2021)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Retinal Blood Vessel Analysis Using Optical Coherence Tomography (OCT) in Multiple Sclerosis
por: Young, Nicholas, et al.
Publicado: (2023)

A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry
por: Hillert, Jan, et al.
Publicado: (2021)

Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers
por: Dolic, Kresimir, et al.
Publicado: (2011)

Relationships Among Circulating Levels of Hemostasis Inhibitors, Chemokines, Adhesion Molecules, and MRI Characteristics in Multiple Sclerosis
por: Ziliotto, Nicole, et al.
Publicado: (2020)

Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021)

Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis
por: Dwyer, Michael G., et al.
Publicado: (2017)

Serum neurofilament light chain levels associations with gray matter pathology: a 5‐year longitudinal study
por: Jakimovski, Dejan, et al.
Publicado: (2019)

Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency
por: Zivadinov, Robert, et al.
Publicado: (2011)

Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients
por: Subramanian, Karthikeyan, et al.
Publicado: (2020)

Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report
por: Zamboni, Paolo, et al.
Publicado: (2011)

Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study
por: Barnett, Michael, et al.
Publicado: (2021)

Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study
por: Schwartz, Carolyn E., et al.
Publicado: (2016)

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study
por: Zivadinov, Robert, et al.
Publicado: (2013)

MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy
por: Goldberg, Hila, et al.
Publicado: (2014)

Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis
por: Caprio, Maria Grazia, et al.
Publicado: (2017)

Proteomics and relationship with axonal pathology in multiple sclerosis: 5-year diffusion tensor imaging study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study
por: Tavazzi, Eleonora, et al.
Publicado: (2020)

Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study
por: Zivadinov, Robert, et al.
Publicado: (2013)

Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis
por: Modica, Claire M., et al.
Publicado: (2017)

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
por: D’Amico, Emanuele, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_88k405brno9mb0c54psj71bp1s